- Home
- TCBS vs PRLD Comparison
TCBS vs PRLD Comparison
Compare TCBS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- PRLD
- Stock Information
- Founded
- TCBS 1934
- PRLD 2016
- Country
- TCBS United States
- PRLD United States
- Employees
- TCBS N/A
- PRLD N/A
- Industry
- TCBS Banks
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- TCBS Finance
- PRLD Health Care
- Exchange
- TCBS Nasdaq
- PRLD Nasdaq
- Market Cap
- TCBS 48.7M
- PRLD 48.6M
- IPO Year
- TCBS N/A
- PRLD 2020
- Fundamental
- Price
- TCBS $16.00
- PRLD $0.93
- Analyst Decision
- TCBS
- PRLD Strong Buy
- Analyst Count
- TCBS 0
- PRLD 2
- Target Price
- TCBS N/A
- PRLD $4.50
- AVG Volume (30 Days)
- TCBS 5.8K
- PRLD 181.0K
- Earning Date
- TCBS 08-12-2025
- PRLD 08-11-2025
- Dividend Yield
- TCBS 1.00%
- PRLD N/A
- EPS Growth
- TCBS N/A
- PRLD N/A
- EPS
- TCBS 0.68
- PRLD N/A
- Revenue
- TCBS $14,488,000.00
- PRLD $7,000,000.00
- Revenue This Year
- TCBS N/A
- PRLD N/A
- Revenue Next Year
- TCBS N/A
- PRLD N/A
- P/E Ratio
- TCBS $23.52
- PRLD N/A
- Revenue Growth
- TCBS 54.08
- PRLD N/A
- 52 Week Low
- TCBS $13.52
- PRLD $0.61
- 52 Week High
- TCBS $19.40
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- TCBS 46.99
- PRLD 59.77
- Support Level
- TCBS $16.01
- PRLD $0.77
- Resistance Level
- TCBS $16.64
- PRLD $0.85
- Average True Range (ATR)
- TCBS 0.69
- PRLD 0.07
- MACD
- TCBS -0.04
- PRLD 0.01
- Stochastic Oscillator
- TCBS 20.93
- PRLD 64.00
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.